GLPwatch
Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.
J Health Popul Nutr · 2025
Last updated 2026-05-28In a study of 219 Japanese patients with diabetes, tirzepatide had a discontinuation rate of about 1.3%, much lower than the 6-10% reported in Western populations. Patients reported reduced cravings for high-fat and high-calorie foods but continued eating traditional low-carbohydrate Japanese foods like fish and meat.
AI summary of the abstract below.
| Journal | J Health Popul Nutr, 2025 |
|---|---|
| Citations | 0 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has demonstrated robust efficacy in clinical trials; however, discontinuation rates due to gastrointestinal adverse events have been reported at 6-10% in Western populations. In contrast, our real-world study of 219 Japanese patients revealed a markedly lower discontinuation rate of approximately 1.3%. Dietary questionnaires indicated that patients experienced reduced appetite for high-fat and high-calorie foods while maintaining consumption of low-carbohydrate traditional Japanese foods such as fish and meat, which may have contributed to the low discontinuation rate.
Verbatim abstract via PubMed 41462404 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.